HCV non-1b genotypes in injecting drug users from Romania

Authors

  • Simona Ruta Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
  • Camelia Sultana Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
  • Cristiana Oprea Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania
  • Codruta Vagu Fundeni Clinical Institute, Bucharest, Romania
  • Emanoil Ceausu Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania
  • Costin Cernescu Stefan S. Nicolau Institute of Virology, Bucharest, Romania

DOI:

https://doi.org/10.3855/jidc.7019

Keywords:

viral hepatitis C, injecting drugs, Romania

Abstract

Introduction: Chronic hepatitis C cases diagnosed in Romania were mostly related to unsafe parenteral treatments and blood transfusions; HCV genotype 1b was prevalent. During the last decade, an increasing number of HCV infections was reported among people who inject drugs (PWID). The aim of the current study was to test if this epidemiological shift triggered a diversification of the circulating viral strains.

Methodology: HCV genotypes were determined by reverse hybridization in 130 HCV-infected PWID (87.7% males; mean age 27.9 ± 6.7 years, injecting drugs for 8.1 ± 4.8 years).

Results: HIV-HCV co-infection was diagnosed in 80.8% of the subjects and 26.9% were HIV-HCV-HBV triple infected. Active HCV viral replication was present in 104 PWID (80%), more frequently in those HIV-co-infected (91.4% vs. 52% in HCV mono-infected, and 77.148.5% in HIV-HCV-HBV triple-infected, p = 0.0001). Non-1b genotypes were prevalent (54.8%), with subtype 1a the most commonly detected (24%), followed by genotypes 3a (14.4%) and 4 (7.7%). Mixed infections with genotypes 1a and 1b were found in nine subjects (8.7%). There was no difference in the genotypes frequencies based on HIV or HBV co-infection status, length of drug usage, or associated risk factors (tattoos, piercing, detention).

Conclusion: The continuous surveillance of HCV genotypes in PWID from Romania will add valuable information to the overall European epidemiological picture, with important therapeutic implications.

Author Biographies

Simona Ruta, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

1. Virology Discipline, Carol Davila University of  Medicine and Pharmacy, Bucharest, Romania

2. Department of Emergent Viral Diseases, Stefan S. Nicolau Institute of Virology, Bucharest, Romania

Camelia Sultana, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

1. Virology Discipline, Carol Davila University of  Medicine and Pharmacy, Bucharest, Romania

2. Department of Emergent Viral Diseases,  Stefan S. Nicolau Institute of Virology, Bucharest, Romania

Cristiana Oprea, Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania

HIV Clinic, Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania

Codruta Vagu, Fundeni Clinical Institute, Bucharest, Romania

Biochemical Department, Fundeni Clinical Institute, Bucharest, Romania

Emanoil Ceausu, Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania

HIV Clinic, Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania

Costin Cernescu, Stefan S. Nicolau Institute of Virology, Bucharest, Romania

Department of Emergent Viral Diseases, Stefan S. Nicolau Institute of Virology, Bucharest, Romania

Downloads

Published

2016-05-31

How to Cite

1.
Ruta S, Sultana C, Oprea C, Vagu C, Ceausu E, Cernescu C (2016) HCV non-1b genotypes in injecting drug users from Romania. J Infect Dev Ctries 10:523–527. doi: 10.3855/jidc.7019

Issue

Section

Brief Original Articles